Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia

Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Feb 2019

At a glance

  • Drugs SM 04554 (Primary)
  • Indications Alopecia
  • Focus Registrational; Therapeutic Use
  • Sponsors Samumed
  • Most Recent Events

    • 22 Nov 2018 New trial record
    • 19 Nov 2018 According to a Samumed media release, this study is conducted under an IND with the FDA. In addition, the Ministry of Health of Turkey has confirmed that the study, if successful, would support submission of a marketing application for SM04554 in Turkey.
    • 19 Nov 2018 According to a Samumed media release, first patient has been dosed in the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top